Because of the chronic relapsing nature of inflammatory bowel disease (IBD), emergency clinicians frequently manage patients with acute flares and complications. IBD patients present with an often-broad range of nonspecific signs and symptoms, and it is essential to differentiate a mild flare from a life-threatening intra-abdominal process. Recognizing extraintestinal manifestations and the presence of infection are critical. This issue reviews the literature on management of IBD flares in the emergency department, including laboratory testing, imaging, and identification of surgical emergencies, emphasizing the importance of coordination of care with specialists on treatment plans and offering patients resources for ongoing support.
At the start of your shift, you log on and click into your first ED chart of the day and sigh, “Not again.” It’s the chart of one of your “frequent flyers,” a young woman who has come to the ED several times in the past few months with a variety of nonurgent complaints. Itching eyes is one. “I seem to be tired all the time,” is another. “I have fevers sometimes.” “My muscles ache. My joints hurt sometimes.” Her workups are always unrevealing. She carries multiple diagnoses, many nonspecific: anemia, possible depression, medication-seeking behavior, myalgias, possible malingering, etc. Today’s chief complaint is abdominal pain. “It's going to be a heck of a day, if this is the start of it,” you think, but remembering how bias can cloud decision-making, you take a deep breath and enter the exam room...
Your next patient is a 40-year-old man with long-standing ulcerative colitis, well known to your institution, who has come in many times for UC flares. Today though, his first words to you are, “I’m sicker than usual.” Glancing at his chart, you notice that he has a fever and a heart rate of 117 beats/min. He looks moderately ill, although it’s hard to assess him completely, since he is fully clothed and clutching his belly, hunched over and groaning. You recall that this is not entirely different from many other ED visits for this patient. You wonder how to sort through his presentation. Is this just another UC flare … or something more sinister?
Crohn disease (CD) and ulcerative colitis (UC) are the 2 major forms of inflammatory bowel disease (IBD). CD can affect any portion of the alimentary tract, from the mouth to the anus, and is a transmural process. UC, as the name implies, affects the colon’s mucosal lining. A 2004 literature review estimated that 1.4 million people in North America and 2.2 million in Europe have IBD.1 It is highly likely that there are many people with IBD who are undiagnosed. Approximately 25% of IBD patients are diagnosed in their first 2 decades of life, with an increased incidence reported in teens.2,3
The annual number of emergency department (ED) visits in the United States for IBD-related complaints is unknown. However, due to IBD’s chronic relapsing nature and the complications associated with the condition, the public health burden of disease is substantial.4 Per the Crohn’s & Colitis Foundation website,5 there were 1.1 million ambulatory care visits for CD and another 716,000 for UC in 2004. The same site estimates that the annual financial burden of IBD in the United States is over $31 billion.
Because patients with IBD often present to the ED acutely decompensating, the emergency clinician must have a systematic approach to evaluation and management and must be familiar with therapeutic strategies needed to stabilize the patient. More challenging is the patient with undiagnosed IBD, and familiarity with the symptom complex and diagnostic criteria can help ensure that these patients receive the specialty care they need. This issue of Emergency Medicine Practice provides a systematic review of the literature on IBD, with best-practice recommendations incorporating advances in diagnostics and therapeutics.
There is a vast and rapidly growing body of IBD literature, but most of it has been published outside of traditional emergency medicine journals. To focus on the IBD literature relevant to emergency practice, we limited most of our review to literature published since 2006 and crossed the terms inflammatory bowel disease with the search terms emergency, complications, treatment, and emergency department. Adding [AND] emergency to the original inflammatory bowel disease PubMed search string produced 20 references, 13 within the last 10 years, with 2 from the emergency medicine literature. In addition to PubMed searches, the Cochrane Database of Systematic Reviews, the National Guidelines Clearinghouse, and various gastrointestinal medical society websites and patient-centered IBD websites were searched. These sources provided articles primarily on long-term care and other nonemergent IBD-related issues. However, a great deal of useful information on acute IBD flares was gleaned from guidelines provided on the American Gastroenterological Association website (www.gastro.org). Where prospective randomized studies were available and relevant to ED care, we attempted to preferentially present data from these studies.
1. “He came in with painful bumps on his shins, anemia, and some joint pain; how was I to know it was IBD?”
The painful shin bumps may be erythema nodosum, a dermatologic manifestation of IBD. Anemia, which may be multifactorial, often coexists with IBD. Finally, musculoskeletal manifestations are perhaps the most common of the extraintestinal manifestations of IBD. These findings and many others often coexist with, and flare with, IBD disease activity.
2. “I give antibiotics to every IBD patient with a disease flare.”
Consider checking with your patient’s gastroenterologist, but try to save the antibiotics to treat those with a high likelihood of, or proof of, a bacterial infection. Infectious colitis, toxic megacolon, bowel perforation, intra-abdominal abscess and other infections (pyelonephritis, cholecystitis) are indications for antibiotics. Admittedly, it can be difficult to distinguish a “flaring” patient from an infected one, since both may have temperature elevations and laboratory findings indicating possible infection. Flare due to infection or coexisting with infection is possible as well.
3. “I can’t CT everyone with abdominal pain and bloody stools.”
That’s a true statement, nor should you obtain a CT on every IBD patient with abdominal pain and bloody stools. However, certain IBD patients need imaging, and CT may the most expeditious way to get the information you need to care for these individuals. Consider CT (or alternate imaging, if feasible) in IBD patients for whom there is a concern for IBD-related surgical emergencies or other abdominopelvic but non- IBD-related diagnoses: for example, patients with severe pain and signs of sepsis.
4. “All the lab results are normal; she can’t have IBD.”
Many laboratory abnormalities are associated with IBD, IBD flares, medications effects, and disease complications. However, normal laboratory results, while perhaps reassuring, do not rule out IBD.
5. “IBD is rare in children.”
It is not rare at all: about 25% of IBD diagnoses are made in the pediatric age group. Include IBD in the differential diagnosis of children with aphthous ulcers, arthritic complaints, and growth delay, and refer them for workup.
6. “It was just a urinary tract infection. I didn’t know she’d bounce back to the ED septic.”
IBD patients are immunocompromised, and as a result, they are at increased lifetime risk for infections, sepsis, and end-organ failure. Infectious complications are a major cause of mortality in IBD patients. Be extra careful with IBD patients who have concurrent infections. A brief “admit for observation” may be a helpful strategy in this group, even if they’re not particularly ill-appearing.
7. “I’ve never seen a patient with toxic megacolon. How would I even know to suspect it?”
Broadly defined, toxic megacolon is a nonobstructive colonic dilation alongside systemic toxicity. As you assess sicker IBD patients in the ED (and those with toxic megacolon will be among the sickest IBD patients you will see) look for signs of sepsis, marked vital sign abnormalities consistent with shock, dehydration, anemia, and leukocytosis. Consider stat acute abdominal series radiographs. A toxic patient with colonic dilation ≥ 6 cm on a supine abdominal radiograph should alert you to the diagnosis.
8. “There are so many IBD medications now, I can’t keep them all straight.”
A general understanding of the 5 broad medication classes as outlined in this review will be helpful, along with a few facts about the major adverse effects one can see with some of the medications. Corticosteroids remain the cornerstone of IBD flare therapy. Oral corticosteroids can be used for mild outpatient flares. High-dose intravenous corticosteroids are used for the sicker admitted patients.
9. “The easiest and best way for me to treat IBD patients with abdominal pain is to check all the labs, rehydrate, treat pain, and do a CT.”
That may be a completely reasonable and necessary approach, but only for a subset of IBD patients. All IBD patients in the ED do not need the same workup, particularly the CT.
10. “Aside from opioids, there are no other medications to treat IBD symptoms.”
Dehydration is miserable, but it is easily treated with either oral or intravenous rehydration. Fever and nausea cause misery as well. Both can generally be treated to resolution in the ED. Consider benzodiazepines for tenesmus (and anxiety, if that is an issue). Consider also the potential opioid-sparing effect of ketamine, a medication with almost no absolute contraindications.
Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.
To help the reader judge the strength of each reference, pertinent information about the study is included in bold type following the reference, where available. In addition, the most informative references cited in this paper, as determined by the authors, are noted by an asterisk (*) next to the number of the reference.
Episode 10 Shownotes | Management of Inflammatory Bowel Disease Flares in the Emergency Department
Because of the chronic relapsing nature of inflammatory bowel disease (IBD), emergency clinicians frequently manage patients with acute flares and complications. IBD patients present with an often-broad range of nonspecific signs and symptoms, and it is essential to differentiate a mild flare from a life-threatening intra-abdominal process. Recognizing extraintestinal manifestations and the presence of infection are critical. This episode reviews the literature on management of IBD flares in the emergency department, including laboratory testing, imaging, and identification of surgical emergencies, emphasizing the importance of coordination of care with specialists on treatment plans and offering patients resources for ongoing support
This episode of EB Medicine’s EMplify podcast is hosted by Jeff Nusbaum, MD, and Nachi Gupta, MD, PhD. This month’s corresponding full-length journal issue of Emergency Medicine Practice was authored by Dr. Michael Burg and Dr. Steven Riccoboni. It was peer reviewed by Dr. Andrew Lee and Dr. Chad Roline.
Follow The Podcast
Michael D. Burg, MD; Steven T. Riccoboni, MD
November 1, 2017
November 30, 2020
4 AMA PRA Category 1 Credits™, 4 ACEP Category I Credits, 4 AAFP Prescribed Credits, 4 AOA Category 2-A or 2-B Credits. Specialty CME Credits: Included as part of the 4 credits, this CME activity is eligible for 1 Pharmacology CME credit
Date of Original Release: November 1, 2017. Date of most recent review: October 10, 2017. Termination date: November 1, 2020.
Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME.
Credit Designation: EB Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACEP Accreditation: Emergency Medicine Practice is approved by the American College of Emergency Physicians for 48 hours of ACEP Category I credit per annual subscription.
AAFP Accreditation: This Enduring Material activity, Emergency Medicine Practice, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 07/01/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 4 AAFP Prescribed credits.
AOA Accreditation: Emergency Medicine Practice is eligible for up to 48 American Osteopathic Association Category 2-A or 2-B credit hours per year.
Specialty CME: Included as part of the 4 credits, this CME activity is eligible for 1 Pharmacology CME credit, subject to your state and institutional approval.
Needs Assessment: The need for this educational activity was determined by a survey of medical staff, including the editorial board of this publication; review of morbidity and mortality data from the CDC, AHA, NCHS, and ACEP; and evaluation of prior activities for emergency physicians.
Target Audience: This enduring material is designed for emergency medicine physicians, physician assistants, nurse practitioners, and residents.
Goals: Upon completion of this activity, you should be able to: (1) demonstrate medical decision-making based on the strongest clinical evidence; (2) cost-effectively diagnose and treat the most critical presentations; and (3) describe the most common medicolegal pitfalls for each topic covered.
Discussion of Investigational Information: As part of the journal, faculty may be presenting investigational information about pharmaceutical products that is outside Food and Drug Administration–approved labeling. Information presented as part of this activity is intended solely as continuing medical education and is not intended to promote off-label use of any pharmaceutical product.
Faculty Disclosure: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Burg, Dr. Riccoboni, Dr. Lee, Dr. Roline, Dr. Mishler, Dr. Toscano, and their related parties report no significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation. Dr. Jagoda made the following disclosures: Consultant, Daiichi Sankyo Inc; Consultant, Pfizer Inc; Consultant, Banyan Biomarkers Inc; Consulting fees, EB Medicine.
Earning Credit: Two Convenient Methods: (1) Go online to www.ebmedicine.net/CME and click on the title of the article. (2) Mail or fax the CME Answer And Evaluation Form (included with your June and December issues) to EB Medicine.
Hardware/Software Requirements: You will need a Macintosh or PC to access the online archived articles and CME testing.
Additional Policies: For additional policies, including our statement of conflict of interest, source of funding, statement of informed consent, and statement of human and animal rights, visit www.ebmedicine.net/policies